Main Article Content
Background: Prostate cancer remains the most common cancer in men worldwide and in Sudanese people. The initial treatment of choice for prostate cancer is androgen deprivation. If resistant to treatment, this leads to a state termed metastatic castration-resistant prostate cancer (mCRPC) which leads to the use of Docetaxel(Taxotere) which has been a mainstay of therapy for patients with mCRPC.
This study aimed to determine the optimal number of cycles of DOcetaxel plus prednisone in patients with metastatic castration-resistant prostate cancer, through the evaluation of a number of parameters, such as performance status, prostate-specific antigen response and pain
Methods: Retrospective study of (60) metastatic castration-resistant prostate cancer (mCRPC) Sudanese patients who received Docetaxel plus prednisone (duration, 2013–2017).
Area; The Radiation and Isotopes Centre of Khartoum (RICK).Data collected by reviewing medical of records of patients confirmed (mCRPC).
Outcomes: Including: performance status, prostate-specific antigen (PSA) response and pain. According to this study we found that docetaxel has an effective role in the treatment of mCRPC patients with an optimal number of6–8 cycles every 3 weeks and with a dose of 75 mg
Conclusion: The benefits for using Docetaxel for mCRPC Sudanese patients: declined of PSA serum level, improvement of performance status and pain reduction. Effective optimal number of cycles 6 to 8 every 3 weeks and dose of 75 mg